High-affinity agonist binding correlates with efficacy (intrinsic activity) at the human serotonin 5-HT(2A) and 5-HT(2C) receptors: Evidence favoring the ternary complex and two-state models of agonist action

Journal of Neurochemistry

Volumn 72, Issue 5, 1999, Pages 2127-2134

  Fitzgerald, Lawrence W ^a   Conklin, Deborah S ^a   Krause, Carol M ^a   Marshall, Anne P ^a   Patterson, John P ^a   Tran, David P ^a   Iyer, Geeta ^a   Kostich, Walter A ^a   Largent, Brian L ^a   Hartig, Paul R ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Episomal expression; Intrinsic activity; Inverse agonism; RNA editing

Indexed keywords

3 METHYLSPIPERONE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); IODINE 125; MESULERGINE; SEROTONIN 2A AGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; TRITIUM;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; EMBRYO; HUMAN; HUMAN CELL; HYDROLYSIS; LIGAND BINDING; PHOSPHOINOSITIDE METABOLISM; PRIORITY JOURNAL; RECEPTOR AFFINITY;

AMPHETAMINES; BINDING, COMPETITIVE; CELL LINE; ERGOLINES; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; HYDROLYSIS; ISOMERISM; LIGANDS; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOLS; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SPIPERONE;

TRITIUM;

EID: 0033014103     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1999.0722127.x     Document Type: Article

References (36)

1. 2C receptors reveal novel inverse agonism activity of receptor ligands. J. Biol. Chem. 269, 11687-11690.
2. Berg K. A., Maayani S., Goldfarb J., Scaramellini C., Leff P., and Clarke W. P. (1998) Effector-pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol. Pharmacol. 54, 94-104.
3. Berridge M. J., Downes P. C., and Hanley M. R. (1982) Lithium amplifies agonist-dependent phosphatidylinositol response in brain and salivary glands. Biochem. J. 206, 587-595.
4. Bradford M. M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
5. Bruns R. F. (1996) Conformational induction versus conformation selection: evidence from allosteric enhancers. Trends Pharmacol. Sci. 17, 189.
6. Burns C. M., Chu H., Rueter S. M., Hutchinson L. K., Canton H., Sanders-Bush E., and Emeson R. B. (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature 387, 303-308.
7. Clarke W. P. and Bond R. A. (1998) The elusive nature of intrinsic efficacy. Trends Pharmacol. Sci. 19, 270-276.
8. De Lean A., Stadel J. M., and Lefkowitz R. J. (1980) A ternary complex explains the agonist-specific binding properties of the adenylate cyclase-coupled β-adrenergic receptor. J. Biol. Chem. 255, 7108-7117.
9. 2C receptors. Psychopharmacology (Berl.) 136, 409-414.
10. Ehlert F. J. (1985) The relationship between muscarinic receptor occupancy and adenylate cyclase inhibition in the rabbit myocardium. Mol. Pharmacol. 28, 410-427.
11. Friessmuth M., Casey P. J., and Gilman A. G. (1989) G proteins control diverse pathways of transmembrane signaling. FASEB J. 3, 2125-2131.
12. Gerhardt C. C. and van Heerikhuizen H. (1997) Functional characteristics of heterologously expressed 5-HT receptors. Eur. J. Pharmacol. 334, 1-23.
13. 2C RNA editing alters receptor constitutive activity. Soc. Neurosci. Abstr. 24, 1098.
14. Horlick R. A., Sperle K., Breth L. A., Reid C. C., Shen E. S., Robbinds A. K., Cooke G. M., and Largent B. L. (1997) Rapid generation of stable cell lines expressing corticotropin-releasing hormone receptor for drug discovery. Protein Expr. Purif. 9, 301-308.
15. Iyer G., Tran D. P., Conklin D. S., Patterson J., Krause C., Fitzgerald L. W., Hartig P., and Jonak G. J. (1998) Identification and characterization of 5HT2C receptor edited isoforms in human brain. Soc. Neurosci. Abstr. 24, 1098.
16. Julius D., MacDermott A. B., Axel R., and Jessell T. M. (1988) Molecular characterization of a functional cDNA encoding the serotonin-1c receptor. Science 241, 558-564.
17. Kenakin T. (1995a) Agonist-receptor efficacy. I. Mechanisms of efficacy and receptor promiscuity. Trends Pharmacol. Sci. 16, 188-192.
18. Kenakin T. (1995b) Agonist-receptor efficacy. II: Agonist trafficking of receptor signals. Trends Pharmacol Sci. 16, 232-238.
19. Kenakin T. (1996) Receptor conformation induction versus selection: all part of the same energy landscape. Trends Pharmacol. Sci. 17, 190-191.
20. Kent R. S., De Lean A., and Lefkowitz R. J. (1980) A quantitative analysis of beta-adrenergic receptor interactions: resolution of high and low-affinity states of the receptor by computer modeling of ligand binding data. Mol. Pharmacol. 17, 14-23.
21. Lahti R. A., Figur L. M., Piercey M. F., Ruppel P. L., and Evans D. L. (1992) Intrinsic activity determinations at the dopamine D2 guanine nudeotide-binding protein-coupled receptor: utilization of receptor state binding affinities. Mol. Pharmacol. 42, 432-438.
22. Leff P. (1995) The two-state model of receptor activation. Trends Pharmacol. Sci. 16, 89-97.
23. Leff P., Scaramellini C., Law C., and McKechnie K. (1997) A three-state model of agonist action. Trends Pharmacol. Sci. 18, 355-362.
24. Lefkowitz R. J., Cotecchia S., Samara P., and Costa T. (1993) Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci. 14, 303-307.
25. Neer E. J. (1995) Heterotrimeric G proteins: organizers of transmembrane signals. Cell 80, 249-257.
26. 2C receptors expressed in the human neuroblastoma cell line SH-SY5Y: comparative stimulation by hallucinogenic drugs. J. Neurochem. 67, 2521-2531.
27. 2C RNA transcripts. Soc. Neurosci. Abstr. 24, 1098.
28. Pardo L., Campillo M., and Giraldo J. (1997) The effect of the molecular mechanism of G protein-coupled receptor activation on the process of signal transduction. Eur. J. Pharmacol. 335, 73-87.
29. 2 receptors: membrane homogenate and autoradiographic studies. J. Pharmacol. Exp. Ther. 286, 459-468.
30. Roth B. L., Choudhary M. S., Khan N., and Uluer A. Z. (1997) High-affinity agonist binding is not sufficient for agonist efficacy at 5-hydroxytryptamine2A receptors: evidence in favor of a modified ternary complex model. J. Pharmacol. Exp. Ther. 280, 576-583.
31. 2C): where structure meets function. Pharmacol. Ther. 79, 231-257.
32. 2-adrenergic receptor. Extending the ternary complex model. J. Biol. Chem. 268, 4625-4636.
33. Surya A., Stadel J. M., and Knox B. E. (1998) Evidence for multiple biochemically distinguishable states in the G protein-coupled receptor, rhodopsin. Trends Pharmacol. Sci. 19, 243.
34. Westphal R. S. and Sanders-Bush E. (1994) Reciprocal binding properties of 5-hydroxytryptamine type 2C receptor agonists and inverse agonists. Mol. Pharmacol. 46, 937-942.
35. Wreggett K. A. and De Lean A. (1984) The ternary complex model: its properties and interactions with the D2 dopamine receptor of the anterior pituitary. Mol. Pharmacol. 26, 214-227.
36. Zahniser N. and Molinoff P. B. (1978) Effect of guanine nucleotides on striatal dopamine receptors. Nature 275, 453-455.